1. Home
  2. IMAX vs PVLA Comparison

IMAX vs PVLA Comparison

Compare IMAX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imax Corporation

IMAX

Imax Corporation

HOLD

Current Price

$52.12

Market Cap

2.4B

Sector

N/A

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$126.21

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMAX
PVLA
Founded
1967
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.9B
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
IMAX
PVLA
Price
$52.12
$126.21
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$60.00
★ $228.93
AVG Volume (30 Days)
★ 953.9K
193.5K
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
31.25
★ 52.62
EPS
★ 0.35
N/A
Revenue
★ $410,212,000.00
$42,810,000.00
Revenue This Year
$18.11
N/A
Revenue Next Year
$2.04
N/A
P/E Ratio
$152.09
★ N/A
Revenue Growth
16.47
★ 65.28
52 Week Low
$31.27
$68.96
52 Week High
$57.73
$161.38

Technical Indicators

Market Signals
Indicator
IMAX
PVLA
Relative Strength Index (RSI) 48.72 40.80
Support Level $50.03 $119.42
Resistance Level $55.57 $136.35
Average True Range (ATR) 1.73 6.61
MACD 0.04 0.30
Stochastic Oscillator 63.59 34.87

Price Performance

Historical Comparison
IMAX
PVLA

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: